Insulin Glargine (Lantus) Overdose: Recognition, Emergency Response, and Prevention

Why Insulin Glargine Overdose Differs from Other Insulin Types

Insulin glargine produces a uniquely prolonged hypoglycemic threat because of how the molecule behaves after injection. Unlike rapid-acting insulins that peak within 1 to 2 hours and clear in 4 to 6 hours, glargine forms microprecipitates in subcutaneous tissue at physiological pH of 7.4, creating a slow-release depot that provides absorption over roughly 24 hours [1].

This depot pharmacokinetics is the single most important fact for anyone managing a glargine overdose. The FDA-approved prescribing information for Lantus states that insulin glargine has "no pronounced peak" and provides "a relatively constant concentration/time profile over 24 hours" [1]. In overdose, this translates to a protracted window during which blood glucose can drop repeatedly. A patient who appears to recover after initial glucose rescue may develop recurrent hypoglycemia 6, 12, or even 18 hours later as the subcutaneous depot continues releasing insulin into the bloodstream.

The ORIGIN trial (N=12,537) demonstrated that insulin glargine, even at therapeutic doses titrated to a fasting glucose target of 95 mg/dL or below, carried a confirmed severe hypoglycemia rate of 1.00 event per 100 person-years in the insulin group versus 0.31 in the standard-care group [2]. This 3-fold increase at therapeutic doses underscores how sensitive the margin is. Supratherapeutic doses amplify this risk enormously.

The American Diabetes Association (ADA) defines hypoglycemia at three levels: Level 1 (glucose <70 mg/dL), Level 2 (glucose <54 mg/dL), and Level 3 (any event with "severe cognitive impairment requiring external assistance for recovery") [3]. Glargine overdose can progress through all three levels over a time course that outlasts most other insulin formulations.

Recognizing an Insulin Glargine Overdose

The symptoms of glargine overdose are the symptoms of hypoglycemia, and they follow a predictable neurological gradient. Early adrenergic signs appear first. Late neuroglycopenic signs follow if glucose continues to fall.

Adrenergic signs (glucose roughly 55 to 70 mg/dL): tremor, palpitations, sweating, anxiety, hunger, and pallor. These reflect the sympathetic nervous system's counter-regulatory response and serve as the body's alarm system [4].

Neuroglycopenic signs (glucose below approximately 50 mg/dL): confusion, slurred speech, visual disturbance, difficulty concentrating, unusual behavior, and loss of coordination. These indicate that the brain is being deprived of its primary fuel [4].

Severe neuroglycopenia (glucose typically below 40 mg/dL): seizures, loss of consciousness, and coma. The Endocrine Society's 2009 clinical practice guideline defines severe hypoglycemia as an event "requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions" [5].

A critical clinical nuance: patients on beta-blockers may not experience the adrenergic warning symptoms. The tremor, tachycardia, and anxiety can be blunted, allowing glucose to drop to neuroglycopenic levels without warning. Philip Cryer, MD, who led much of the foundational research on hypoglycemia counter-regulation at Washington University, described this phenomenon as part of "hypoglycemia-associated autonomic failure," noting that "the clinical problem of hypoglycemia in diabetes is largely the result of the loss of both key defenses against falling plasma glucose concentrations" [6]. Patients on concurrent beta-blocker therapy who take excess glargine therefore need earlier and more frequent glucose checks.

Immediate At-Home Response: The Rule of 15

For a conscious person who has taken an accidental excess dose and whose blood glucose is dropping but still above 54 mg/dL, the first intervention is oral glucose.

The ADA recommends the "Rule of 15": consume 15 grams of fast-acting carbohydrate, wait 15 minutes, and recheck blood glucose [3]. If glucose remains below 70 mg/dL, repeat. Suitable sources of 15 grams of fast-acting carbohydrate include 4 glucose tablets, 4 ounces (120 mL) of fruit juice, or 1 tablespoon of sugar dissolved in water. Do not use chocolate, peanut butter crackers, or other fat-containing foods. Fat slows gastric absorption and delays the glucose rise.

Here is where glargine overdose demands extra caution. A single round of 15 grams may temporarily restore glucose, but the ongoing depot absorption will continue pulling glucose down. After the initial correction, the patient should:

1. Eat a meal containing complex carbohydrates and protein within 30 minutes.
2. Set a timer to recheck blood glucose every 30 to 60 minutes for the next 12 to 24 hours.
3. Keep glucose tablets and a glucagon kit at the bedside.
4. Not go to sleep without a monitoring plan in place (a family member checking glucose, or a continuous glucose monitor with low-glucose alarms).

If the dose taken exceeds the prescribed dose by more than 50%, or if the patient has any doubt about the amount injected, calling Poison Control (1-800-222-1222 in the United States) or proceeding to the emergency department is the safer choice.

Emergency Department and Inpatient Management

When a patient presents to the emergency department after a significant glargine overdose, the management follows a tiered protocol that prioritizes sustained euglycemia and prolonged observation.

IV dextrose is the backbone of hospital management. A bolus of 25 grams of dextrose (50 mL of D50W, or 250 mL of D10W) restores blood glucose within minutes [7]. For glargine overdose, a continuous D10W infusion at 100 to 200 mL/hour is typically initiated after the initial bolus because the subcutaneous depot will keep releasing insulin. The infusion rate is titrated to maintain blood glucose between 100 and 180 mg/dL [7].

Glucagon serves as a bridge when IV access is not yet established or as an adjunct. The standard dose is 1 mg intramuscular or subcutaneous. Intranasal glucagon (Baqsimi, 3 mg) is an alternative that does not require injection [8]. Glucagon works by stimulating hepatic glycogenolysis, but its effect depends on adequate liver glycogen stores. In malnourished patients, chronic alcohol users, or those who have been fasting, glucagon may be less effective.

Monitoring duration is the area where glargine overdose management most diverges from rapid-acting insulin overdose. The FDA label for Lantus notes that "the prolonged duration of activity of insulin glargine may delay recovery from hypoglycemia" [1]. Published case reports describe recurrent hypoglycemia occurring 12 to 20 hours after the initial dose in patients who appeared stable [9]. A minimum observation period of 24 hours is standard practice for any clinically significant glargine overdose, with blood glucose checked every 1 to 2 hours.

Potassium monitoring is often overlooked but necessary. Insulin drives potassium intracellularly. A large insulin overdose can cause hypokalemia, which predisposes to cardiac arrhythmias. Serum potassium should be checked on arrival and every 4 to 6 hours during the monitoring period, with replacement as needed [7].

Surgical excision of the injection site has been reported in case studies involving massive intentional overdoses (over 1,000 units), though this remains controversial and is not part of standard guidelines [9]. The rationale is to remove the depot before more insulin is absorbed. This approach is considered only in extreme circumstances.

Accidental Excess Dose: How It Happens and What to Do

Accidental glargine overdoses are more common than many clinicians realize. A 2014 analysis of the National Poison Data System found that insulin was involved in approximately 5,900 exposures annually in the United States, with the majority being unintentional [10]. The most frequent scenarios include:

Confusion between basal and bolus insulin. A patient who takes 40 units of rapid-acting insulin (intended as a mealtime dose) from the wrong pen, or who accidentally draws glargine into a syringe thinking it is their rapid-acting insulin. Pen devices that look similar, particularly when stored in the same location, are a known risk factor.

Dose doubling. Forgetting whether the evening dose was already taken and injecting a second time. This is especially common in older adults.

Unit vs. volume confusion. A patient switching from U-100 to U-300 concentration (Toujeo) or vice versa without appropriate dose adjustment. One mL of U-300 contains 300 units, three times the amount in one mL of U-100 [1].

Pediatric accidental exposure. A child gaining access to an insulin pen left on a countertop.

For an accidental double dose of glargine at the patient's usual prescribed amount (say, 30 units taken twice, totaling 60 units instead of 30), the risk is real but manageable at home in most cases. The patient should eat a substantial meal immediately, check blood glucose every 1 to 2 hours, and have someone available to assist through the night. The threshold for seeking emergency care should be low: any glucose reading below 54 mg/dL despite oral carbohydrate correction, any neurological symptom, or inability to maintain frequent glucose checks.

For larger errors (three or more times the prescribed dose, or any dose exceeding 100 units in an insulin-naive individual), emergency department evaluation is warranted regardless of initial glucose readings, because the peak effect may not manifest for several hours.

Prevention Strategies That Actually Reduce Errors

Preventing insulin dosing errors requires systems-level interventions, not just patient education.

Pen labeling and storage separation. The Institute for Safe Medication Practices (ISMP) recommends storing basal and bolus insulin pens in separate locations and applying distinct color-coded labels [11]. Sanofi's Lantus SoloStar pen is gray and purple; ensuring rapid-acting pens are stored in a different drawer or case reduces mix-up risk.

Dose-tracking tools. Connected insulin pens (such as the NovoPen 6 or InPen) automatically log each injection with a timestamp. These devices show the last dose time and amount, directly addressing the "did I already take it?" problem. Continuous glucose monitors (CGMs) with low-glucose alarms (set at 70 mg/dL or the patient's preference) add a safety net that catches falling glucose before symptoms appear.

Concentration awareness. Patients switching between U-100 glargine (Lantus) and U-300 glargine (Toujeo) need explicit counseling that the doses are not interchangeable on a unit-for-unit basis. The FDA safety communication emphasizes that "patients should not transfer insulin from a prefilled pen to a syringe" because this can result in severe dosing errors [12].

Glucagon kit accessibility. Every household with an insulin-using member should have an unexpired glucagon kit. Nasal glucagon (Baqsimi) does not require reconstitution and can be administered by a family member with minimal training. Dasiglucagon (Zegalogue) is a premixed, room-temperature-stable alternative [8]. Both have a shelf life of approximately 24 months. Checking the expiration date monthly should be as routine as checking smoke detector batteries.

Special Populations: Higher Risk, Different Considerations

Certain patient groups face amplified risks from glargine overdose and require modified management approaches.

Older adults (aged 65 and above) have blunted counter-regulatory hormone responses and reduced awareness of hypoglycemia symptoms. The ADA's 2024 Standards of Care recommend a less stringent HbA1c target (below 8.0% rather than below 7.0%) for older adults with multiple comorbidities, in part to reduce hypoglycemia risk [3]. After an accidental excess dose in this population, the threshold for emergency department evaluation should be lower.

Patients with chronic kidney disease (eGFR <30 mL/min/1.73 m²) clear insulin more slowly. The kidneys are responsible for approximately 30 to 80% of peripheral insulin clearance [13]. Reduced renal clearance prolongs the hypoglycemic effect of any insulin dose, including glargine. Case reports document recurrent hypoglycemia lasting 48 hours or more in patients with end-stage renal disease after glargine overdose [9].

Patients with hepatic impairment have reduced glycogen stores, making glucagon less effective and making them more dependent on exogenous glucose for recovery. They also metabolize insulin more slowly, compounding the duration problem.

Patients on concurrent sulfonylureas or meglitinides face dual insulin excess: the exogenous glargine plus enhanced endogenous insulin secretion from the oral agent. This combination can make hypoglycemia more refractory to treatment.

The ORIGIN trial, which enrolled 12,537 participants with early type 2 diabetes or pre-diabetes, reported that participants with an eGFR below 60 experienced a higher incidence of severe hypoglycemia compared to those with preserved renal function (1.6 vs. 0.8 events per 100 person-years) [2]. This finding, while observed at therapeutic doses, reinforces the heightened vigilance needed in renally impaired patients who take excess glargine.

When to Call 911: A Decision Framework

Not every excess dose requires an ambulance, but certain situations demand immediate emergency response.

Call 911 immediately if:

• The person is unconscious, seizing, or unable to swallow safely.
• Blood glucose is below 40 mg/dL and not responding to oral glucose within 15 minutes.
• The person is alone and becoming confused.
• The dose taken exceeds the prescribed amount by a factor of three or more.

Go to the emergency department (drive or be driven) if:

• Blood glucose has dropped below 54 mg/dL on two consecutive checks despite oral carbohydrate.
• The person is on a beta-blocker and cannot reliably detect hypoglycemia symptoms.
• Renal function is significantly impaired (known eGFR <30).
• The person took the wrong concentration (U-300 instead of U-100, or vice versa) and is uncertain of the actual unit dose.

Manage at home with close monitoring if:

• The excess was a single additional dose at the usual prescribed amount.
• Blood glucose is above 70 mg/dL after initial carbohydrate intake.
• A capable adult is available to check glucose every 1 to 2 hours for the next 24 hours.
• A glucagon kit is available and the caregiver knows how to use it.

The Endocrine Society's guideline on hypoglycemia management recommends that "patients at risk for clinically significant hypoglycemia should be taught to recognize and self-treat mild hypoglycemia and should have glucagon available" [5]. This recommendation applies with particular force to every patient prescribed insulin glargine, given its long duration of action and the extended window of risk after any dosing error.

Poison Control (1-800-222-1222) is available 24 hours a day, 7 days a week, and can help triage the severity of an accidental overdose over the phone. Board-certified toxicologists staff the line and can advise on whether home monitoring is appropriate or whether the patient should be transported to an emergency department.